William E. Rosenfeld

Early and sustained responses to cenobamate across focal seizure subtypes 7:01
Early and sustained responses to cenobamate across focal seizure subtypes
William E. Rosenfeld • 4 Apr 2022
Cenobamate for focal seizures: longer-term efficacy and adverse events 2:55
Cenobamate for focal seizures: longer-term efficacy and adverse events
William E. Rosenfeld • 4 Apr 2022
Cenobamate plasma concentrations in 50% and 100% responders 4:47
Cenobamate plasma concentrations in 50% and 100% responders
William E. Rosenfeld • 4 Apr 2022
How to manage patients receiving adjunctive cenobamate 7:02
How to manage patients receiving adjunctive cenobamate
William E. Rosenfeld • 4 Apr 2022
Cognitive and psychiatric adverse events associated with cenobamate 2:38
Cognitive and psychiatric adverse events associated with cenobamate
William E. Rosenfeld • 4 Apr 2022
The content of VJNeurology is intended for healthcare professionals